InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (4 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
4
T+90 hit rate
13%
T+90 mean return
+4.5%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Luly Jay R., Chairman & CEO. Director active across 1 company, notably Enanta Pharmaceuticals INC. Aggregated, 23 disclosures have been logged. Breakdown: 1 buy · 4 sells. Total volume traded: €802k. History available since 15 September 2021. The latest transaction was disclosed on 12 February 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations23 total
25,500 shares0Common StockSEC:0001062993-25-002549:0
45,000 shares@ US$5.699.5% of flowCommon StockSEC:0001062993-25-002225:0
Ideal exit: 9 Nov 2025 (T+270)
5,142 shares@ US$8.061.5% of flowCommon StockSEC:0001062993-24-020375:0
3,829 shares@ US$8.601.2% of flowCommon StockSEC:0001062993-24-019974:0
5,400 shares0Common StockSEC:0001062993-24-003223:0
7,230 shares@ US$9.632.5% of flowCommon StockSEC:0001062993-23-022045:0
5,787 shares@ US$9.491.9% of flowCommon StockSEC:0001062993-23-021981:0
27,912 shares@ US$14.0014.1% of flowCommon StockSEC:0001062993-23-006867:0
22,950 shares0Common StockSEC:0001062993-23-003712:0
15,285 shares0Common StockSEC:0001062993-23-003705:0
14,500 shares@ US$27.5814.6% of flowCommon StockSEC:0001062993-22-024173:0
16,149 shares@ US$14.188.3% of flowCommon StockSEC:0001062993-22-024037:0
5,659 shares@ US$44.339.3% of flowCommon StockSEC:0001062993-22-023359:0
63,000 shares0Common StockSEC:0001062993-22-022837:0
1,627 shares0Common StockSEC:0001062993-22-004510:0
10,063 shares@ US$11.770.027% mcap10.8% of flowCommon StockSEC:0001062993-22-001104:0
10,063 shares@ US$11.774.0% of flowCommon StockSEC:0001062993-22-001104
1,944 shares@ US$87.685.8% of flowCommon StockSEC:0001062993-21-012197
1,944 shares@ US$87.680.039% mcap15.7% of flowCommon StockSEC:0001062993-21-012197:0
25,700 shares0Common StockSEC:0001062993-21-011498:0
25,700 shares0Common StockSEC:0001062993-21-011498
4,516 shares@ US$59.05620.058% mcap23.5% of flowCommon StockSEC:0001177648-21-000025:0
4,516 shares@ US$59.05628.7% of flowCommon StockSEC:0001177648-21-000025
23 of 23 declarations
About Luly Jay R.
Jay R. Luly is the Chief Executive Officer of Enanta Pharmaceuticals Inc. He is responsible for the strategic and operational direction of the company, which focuses on developing innovative medicines. Luly is committed to advancing Enanta's mission.
